Repositorio Dspace

Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801

Mostrar el registro sencillo del ítem

dc.contributor.author Espinosa, Enrique
dc.contributor.author Berciano-Guerrero, Miguel-Ángel
dc.contributor.author Muñoz-Couselo, Eva
dc.contributor.author Puertolas, Teresa
dc.contributor.author Manzano, José-Luis
dc.contributor.author Soria, Ainara
dc.contributor.author Ayala-de-Miguel, Pablo
dc.contributor.author Crespo, Guillermo
dc.contributor.author Gutiérrez-Sanz, Lourdes
dc.contributor.author Cerezuela-Fuentes, Pablo
dc.contributor.author Aguado-de-la-Rosa, Carlos
dc.contributor.author Majem, Margarita
dc.contributor.author García-Castaño, Almudena
dc.contributor.author Berrocal, Alfonso
dc.contributor.author García-Arroyo, Francisco-Ramon
dc.contributor.author Rodríguez-de-la-Borbolla, María
dc.contributor.author Bellido, Lorena
dc.contributor.author Medina-Martínez, Javier
dc.contributor.author Fernández, Luis-Antonio
dc.contributor.author Marín-Carnicero, Alfonso
dc.contributor.author López-Castro, Rafael
dc.contributor.author Bujosa-Rodríguez, Aida
dc.contributor.author Lecumberri, María-José
dc.contributor.author Villa-Guzmán, José-Carlos
dc.contributor.author Campos-Balea, Begoña
dc.contributor.author Rodríguez, Joaquin-Fra
dc.contributor.author Valdivia-Bautista, Javier
dc.contributor.author Navarro-Pérez, Víctor
dc.contributor.author Mujika, Karmele
dc.contributor.author Corral-Subias, Mónica
dc.contributor.author Hernández, Berta
dc.contributor.author Martín-Algarra, Salvador
dc.contributor.author Márquez-Rodas, Iván
dc.date.accessioned 2026-08-03T10:26:39Z
dc.date.available 2026-08-03T10:26:39Z
dc.date.issued 2025-11-28
dc.identifier.issn 1699-048X
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/27135
dc.description.abstract PURPOSE: Anti-PD-1-based immunotherapy and targeted therapies (TT) are the current standard of care for patients with advanced melanoma. However, some patients die in less than a year from diagnosis and others become long-survivors. An accurate description of systemic treatments and patients' characteristics of long-term survivors are needed to guide treatment decisions in clinical practice. METHODS: GEM-1801 is a multi-cohort prospective study from the Spanish Multidisciplinary Melanoma Group that includes patients with resectable stage III or unresectable stage III/IV melanoma. Patients surviving at least 5 years and patients surviving less than 1 year since diagnosis were selected. Baseline characteristics and first and second-line systemic treatments are described and compared between groups. RESULTS: From Aug 2018 to Dec 2023, 60 patients with long-term survival and 216 patients with short-term survival were included. Long-term survivors received immunotherapy (65%), including anti-PD-1 in 86% and combination of an anti-PD-1 and anti-CTLA-4 in 14%; and TT (35%). The Objective Response Rate (ORR) was 76% for anti-PD-1, 80% for combination immunotherapy and 83% for TT. Short-term survivors received immunotherapy (58%), including anti-PD-1 (70%), anti-CTLA-4 (1%), and anti-PD-1 plus anti-CTLA-4 (29%); TT (36%); and chemotherapy (2%). ORR was 7% for anti-PD-1, 0% for anti-CTLA-4, 14% for combination immunotherapy, 53% for TT and 0% for chemotherapy. CONCLUSIONS: Response to first or second-line systemic treatment may be a surrogate for long-term survival patients with advanced melanoma. CLINICAL TRIAL IDENTIFICATION: Clinicaltrials.gov: NCT03605771.
dc.language.iso eng
dc.publisher SPRINGER INT PUBL AG
dc.rights Atribución/Reconocimiento 4.0 Internaciona
dc.rights.uri https://creativecommons.org/licenses/by/4.0/deed.es *
dc.subject.mesh Humans
dc.subject.mesh Melanoma/mortality/pathology/drug therapy/therapy
dc.subject.mesh Prospective Studies
dc.subject.mesh Female
dc.subject.mesh Male
dc.subject.mesh Middle Aged
dc.subject.mesh Aged
dc.subject.mesh Immunotherapy/methods
dc.subject.mesh Adult
dc.subject.mesh Skin Neoplasms/mortality/pathology/drug therapy/therapy
dc.subject.mesh Immune Checkpoint Inhibitors/therapeutic use
dc.subject.mesh Survival Rate
dc.subject.mesh Aged, 80 and over
dc.subject.mesh Programmed Cell Death 1 Receptor/antagonists & inhibitors
dc.subject.mesh CTLA-4 Antigen/antagonists & inhibitors
dc.subject.mesh Molecular Targeted Therapy
dc.subject.mesh Cancer Survivors/statistics & numerical data
dc.title Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801
dc.type info:eu-repo/semantics/article 
dc.identifier.pmid 41313559
dc.relation.publisherversion https://link.springer.com/10.1007/s12094-025-04098-3
dc.type.version info:eu-repo/semantics/publishedVersion 
dc.identifier.doi 10.1007/s12094-025-04098-3
dc.journal.title CLINICAL & TRANSLATIONAL ONCOLOGY
dc.identifier.essn 1699-3055


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento 4.0 Internaciona Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento 4.0 Internaciona

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta